Oct 03, 2022 / 12:30PM GMT
Unidentified Analyst
Next session, allow me to introduce our guests, Ricardo Dolmetsch, President of Research and Development at uniQure. Ricardo, it's a pleasure to have you with us.
Ricardo Dolmetsch - uniQure N.V. - President, Research & Development
Thank you. Thanks for the invitation.
Questions and Answers:
Unidentified AnalystSo to get started, do you mind giving us some introductory comments on uniQure? What the company is about and the general strategy the company is using to combat disease?
Ricardo Dolmetsch - uniQure N.V. - President, Research & Development
Yes. So we're a gene therapy company focused on diseases of the liver and the central nervous system. We have been working on this for more than 20 years. We registered the first gene therapy in the West, which was Glybera. And we now have a pipeline in hemophilia, in Huntington's disease, in Fabry, in temporal lobe epilepsy.
And we are also GMP manufacturers of AAV gene therapies. We have -- we're
Trustpilot
